title: Thirteen years of culture-positive M. bovis-BCG infection in an IL-12Rbeta1 deficient patient: treatment and outcome.
abstract: Patients with mutations in the IFNgamma/IL-12 pathway show an exquisite susceptibility to mycobacterial diseases. An IL-12Rbeta1 deficient patient with impaired intestinal absorption suffered from a 13 year culture-positive Mycobacterium bovis-BCG infection with acquired multidrug resistance. A combined parenteral and enteral anti-mycobacterial treatment, including recombinant IFNgamma, helped to clear his infection.
authors.affiliation: Servicio de Inmunología, Hospital Nacional de Pediatría J.P. Garrahan, Buenos Aires, Argentina. srosenzweig@garrahan.gov.ar
authors.forename: S D
authors.initials: SD
authors.lastname: Rosenzweig
authors.forename: J
authors.initials: J
authors.lastname: Yancoski
authors.forename: A
authors.initials: A
authors.lastname: Bernasconi
authors.forename: S
authors.initials: S
authors.lastname: Krasovec
authors.forename: B E
authors.initials: BE
authors.lastname: Marciano
authors.forename: L
authors.initials: L
authors.lastname: Casimir
authors.forename: G
authors.initials: G
authors.lastname: Berberian
authors.forename: N
authors.initials: N
authors.lastname: Símboli
authors.forename: M
authors.initials: M
authors.lastname: Rousseau
authors.forename: G
authors.initials: G
authors.lastname: Calle
mesh_terms: D000293:Adolescent; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D009163:Mycobacterium bovis / Q000302:isolation & purification*; D053707:Receptors, Interleukin-12 / Q000172:deficiency* / Q000235:genetics; D014376:Tuberculosis / Q000188:drug therapy* / Q000235:genetics* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; C508438:IL12RB1 protein, human; D053707:Receptors, Interleukin-12